Patents by Inventor Molly Reed PERKINS

Molly Reed PERKINS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE
    Publication number: 20230030085
    Abstract: The invention provides improved methods for detecting anti-BCMA CAR expression on T cells. The invention generally provides antibodies and antigen binding fragments thereof, conjugates thereof, and methods of using the same to detect, determine, or measure CAR T cells and/or CAR expression on one or more T cells.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 2, 2023
    Applicant: 2seventy bio, Inc.
    Inventors: KEVIN FRIEDMAN, MOLLY REED PERKINS
  • CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
    Publication number: 20220332780
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (EL15) payloads, as well as compositions and methods of use thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: October 20, 2022
    Inventors: Kutlu Goksu ELPEK, Dhruv Kam SETHI, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER
  • CD79B CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20220226374
    Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express CD79B. The present invention relates to improved compositions and methods for treating cancer. More particularly, the invention relates to improved anti-CD79B chimeric antigen receptors (CARs), genetically modified immune effector cells, and use of these compositions to effectively treat CD79B expressing cancers.
    Type: Application
    Filed: June 14, 2019
    Publication date: July 21, 2022
    Applicant: 2seventy bio, Inc
    Inventors: Kevin FRIEDMAN, Molly Reed PERKINS
  • ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE
    Publication number: 20210261689
    Abstract: The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 26, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Kevin FRIEDMAN, Molly Reed PERKINS
  • CD79A CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210261659
    Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 26, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Kevin FRIEDMAN, Molly Reed PERKINS
  • CA2 compositions and methods for tunable regulation
    Patent number: 11058725
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: July 13, 2021
    Assignee: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
  • CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20210069248
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 11, 2021
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu ELPEK, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER